Latest filing published 08 May 2014 for SCYNEXIS INC.
Insider track record
No signal scores available.
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +37.1%Entry US$2.59 · Close at T+365 US$3.55
- -66.1%Entry US$3.13 · Close at T+365 US$1.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Alta Biopharma Partners II LP: trading record in brief
Alta Biopharma Partners II LP has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Scynexis Inc and Corcept Therapeutics Inc. We count 22 filings; the first trade dates from 25 March 2008 and the latest from 7 May 2014.
Purchases make up the whole of the open-market record (8 purchases, €9.0M). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 8 share grants. 2014 to date brings 2 purchases and no sales.
The median purchase comes to €271k. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -14.2%. This is a record of the past, not a forecast.
The record was last updated on 8 May 2014 with a transaction in Scynexis Inc. The most recent open-market purchase was published on 8 May 2014, 4,568 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Alta Biopharma Partners II LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 161,238 sharesCommon StockSEC:0001209191-14-032428:3
- 50,239 sharesCommon StockSEC:0001209191-14-032428:4
- 69,476 sharesCommon StockSEC:0001209191-14-032428:5
- 4,551 shares@ US$0.20Common StockSEC:0001209191-14-032428:0
- 82,454 shares@ US$0.20Common StockSEC:0001209191-14-032428:2
- 868,066 shares@ US$10.00Common StockSEC:0001209191-14-032428:6Canonical exit: 5 Aug 2014 (T+90)
- 174 shares@ US$0.20Common StockSEC:0001209191-14-032428:7
- 3,033 shares@ US$0.20Common StockSEC:0001209191-14-032428:9
- 5,931 sharesCommon StockSEC:0001209191-14-032428:10
- 1,848 sharesCommon StockSEC:0001209191-14-032428:11
- 2,642 sharesCommon StockSEC:0001209191-14-032428:12
- 31,934 shares@ US$10.00Common StockSEC:0001209191-14-032428:13Canonical exit: 5 Aug 2014 (T+90)
- 337,245 shares@ US$1.38Common StockSEC:0001209191-09-049303:0Canonical exit: 14 Jan 2010 (T+90)
- 12,406 shares@ US$1.38Common StockSEC:0001209191-09-049303:1Canonical exit: 14 Jan 2010 (T+90)
- 103,519 shares@ US$1.45Common StockSEC:0001209191-08-060569:0
- 1,307 shares@ US$1.45Common StockSEC:0001209191-08-060569:1
- 1,045,921 shares@ US$2.77Common StockSEC:0001209191-08-020303:0Canonical exit: 23 Jun 2008 (T+90)
- 13,214 shares@ US$2.77Common StockSEC:0001209191-08-020303:1Canonical exit: 23 Jun 2008 (T+90)
18 of 18 declarations
